Czechia – Antineoplastic and immunomodulating agents – INTERFERON BETA-1A 2026

Decision signals

First-pass opportunity review

These signals are calculated from the indexed fields. They help prioritize a review but do not replace eligibility checks in the official procurement documents.

Timing signal

23 days to indexed deadline

24 September 2026

Indexed data completeness

100%

Based on seven decision fields

Official title coverage

7 languages

Preserved from source-supplied versions

Classification signal

33652000

Medical equipment, pharmaceuticals and personal care products

90-day market activity

68 related notices

22 buyers in Czechia / Pharma and laboratory

Buyer activity

110 indexed notices

Published by this buyer in the last 90 days

Market context

How this notice compares with the current market

Biderra found 68 pharma and laboratory notices from Czechia in its rolling 90-day index. 91% publish an estimated value and 40% include at least one indexed deadline. This notice is currently active according to the deadline fields available in the source feed.

Official title versions

TED may publish the same notice title in several official languages. Biderra preserves the versions supplied in the source feed.

What Biderra adds

For notice 578979-2026, Biderra has normalized the contracting authority country as Czechia, grouped CPV 33652000 under pharma and laboratory, compared the available deadline fields with today, measured field completeness, and preserved 7 source-supplied title versions. The official record remains decisive.